Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib, Binimetinib, and Pembrolizumab in BRAF-mutant Melanoma (PORTSIDE)
NCT05926960Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of encorafenib and binimetinib in melanoma, sponsored by Pfizer. Primary endpoint: Objective Response Rate at 48 months. Started Jun 2023; status: terminated.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05926960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926960.